Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; Association with patient survival

Human Pathology

Volumn 44, Issue 8, 2013, Pages 1638-1647

  Gan, Alex ^a   Green, Andrew R ^b   Nolan, Christopher C ^b   Martin, Stewart ^b   Deen, Suha ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

BRCA; Ovarian cancer; PARP; Serous carcinoma

Indexed keywords

BRCA1 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CORRELATIONAL STUDY; DISEASE SEVERITY; FEMALE; GENE MUTATION; HIGH GRADE SEROUS CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MINIMAL RESIDUAL DISEASE; OVARY CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT RESPONSE;

BRCA; OVARIAN CANCER; PARP; SEROUS CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; GENES, BRCA1; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880333946     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.01.015     Document Type: Article

References (35)

1. R.A. Soslow Histologic subtypes of ovarian carcinoma: an overview Int J Gynecol Pathol 27 2008 161 174
2. T.J. Duncan, P. Rolland, and S. Deen Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer Clin Cancer Res 13 2007 4139 4145
3. D.C. Corney, A. Flesken-Nikitin, and J. Choi Role of p53 and Rb in ovarian cancer Adv Exp Med Biol 622 2008 99 117
4. S.J. Ramus, and S.A. Gayther The contribution of BRCA1 and BRCA2 to ovarian cancer Mol Oncol 3 2009 138 150
5. A. Tinelli, A. Malvasi, and G. Leo Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal Cancer Metastasis Rev 29 2010 339 350
6. J.E. Quinn, J.R. Carser, and C.D. James BRCA1 and implications for response to chemotherapy in ovarian cancer Gynecol Oncol 113 2008 134 142
7. N. Turner, A. Tutt, and A. Ashworth Hallmarks of "BRCAness" in sporadic cancers Nat Rev Cancer 4 2004 1 6
8. W.Z. Wysham, P. Mhawech-Fauceglia, and H. Li BRCAness profile of sporadic ovarian cancer predicts disease recurrence PLoS One 7 2012 e30042
9. C. Annunziata, and J. O'Shaughnessy Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer Clin Cancer Res 16 2010 4517 4526
10. C. Underhill, M. Toulmonde, and H. Bonnefoi A review of PARP inhibitors: from bench to bedside Ann Oncol 22 2010 268 279
11. P. de Graeff, J. Hall, and A. Crijns Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies Curr Probl Cancer 35 2011 7 50
12. F.J. Oliver, G. de la Rubia, and V. Rolli Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis J Biol Chem 273 1998 33533 33539
13. S. Banerjee, and S. Kaye The role of targeted therapy in ovarian cancer Eur J Cancer 47 Suppl 3 2011 Sep S116 S130
14. P.C. Fong, D.S. Boss, and T.A. Yap Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
15. A. Tutt, M. Robson, and J.E. Garber Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 2010 235 244
16. J.A. Ledermann, P. Harter, and C. Gourley Phase II randomised placebo-controlled study of Olaparib (AZD2281) in women with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) J Clin Oncol 29 2011 Suppl.;abstr 5003
17. L. Quattrocchi, A.R. Green, and S. Martin The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression Virchows Arch 459 2011 21 29
18. M. Markman, and W. Hoskins Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population J Clin Oncol 10 1992 513 514
19. T. Bjorge, A. Engeland, and S. Hansen Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993 Int J Cancer 75 1998 663 670
20. E.A. Eisenhauer, P. Therasse, and J. Bagaerts New response evaluation criteria in solid tumors: revised RECIT guideline (version 1.1) Eur J Cancer 45 2009 228 247
21. T.J. Duncan, A. Al-Attar, and P. Rolland Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 14 2008 3030 3035
22. D.G. Rosen, X. Huang, and M.T. Deavers Validation of tissue microarray technology in ovarian carcinoma Mod Pathol 17 2004 790 797
23. R. Camp, L. Charette, and D. Rimm X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization Lab Invest 80 2000 1943 1949
24. D. Shibata, W.J. Martin, and N. Arnheim Analysis of DNA sequences in forty-year-old paraffin-embedded thin-tissue sections: a bridge between molecular biology and classical histology Cancer Res 48 1988 4564 4566
25. K.S. McCarty, L.S. Miller, and E.B. Cox Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies Arch Pathol Lab Med 109 1985 716 721
26. R.L. Camp, and M. Dolled-Filhart X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization Clin Cancer Res 10 2004 7252 7259
27. A. Skytte, M. Waldstrom, and A.A. Ramussen Identification of BRCA1-deficient ovarian cancers ACTA Obstet Gynecol 90 2011 593 599 25
28. F. Magdinier, S. Ribieras, and G.M. Lenoir Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region Oncogene 17 1998 3169 3176
29. J.I. Weberpals, K.V. Clark-Knowles, and B.C. Vanderhyden Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway J Clin Oncol 26 2008 3259 3267
30. J. Boyd, Y. Sonoda, and M.G. Federici Clinicopathologic features of BRCA-linked and sporadic ovarian cancer J Am Med Assoc 283 2000 2260 2265
31. Y. Ben David, A. Chetrit, and G. Hirsh-Yechezkel Effect of BRCA mutations on the length of survival in epithelial ovarian tumors J Clin Oncol 20 2002 463 466
32. A. Chetrit, G. Hirsh-Yechezkel, and Y. Ben-David Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer J Clin Oncol 26 2008 20 25
33. B.T. Hennessy, K.M. Timms, and M.S. Carey Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer J Clin Oncol 28 2010 3570 3576
34. H. Brustmann Poly (adnosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome Int J Gynecol Pathol 26 2007 147 153
35. H. Godoy, P. Mhawech-Fauceglia, and A. Beck Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome Int J Gynecol Pathol 30 2011 139 144